Closed |
S1204 |
Viral Screening Study |
8/29/2013 |
2/15/2017 |
100% |
|
|
Closed |
S1312 |
PI/II Inotuzumab + CVP for R/R CD22+ ALL |
4/1/2014 |
8/2/2019 |
100% |
|
|
Closed |
S1304 |
RPII Dex + High or Low Dose Carfilzomib for R/R MM |
10/18/2013 |
5/15/2016 |
100% |
|
|
Closed |
S1320 |
Melanoma - Ph II Intermittent vs Continuous Dabrafenib and Trametinib BRAF Positive Melanoma |
7/22/2014 |
7/15/2019 |
100% |
|
|
Closed |
S1314 |
Phase II COXEN Trial for Localized Bladder Cancer |
7/9/2014 |
12/1/2017 |
100% |
|
|
Closed |
S1406 |
Rano Ph II of Irino+Cetuximab +/- Vemurafenib in BRAF mutant mCRC |
11/13/2014 |
4/1/2016 |
100% |
|
|
Closed |
S1316 |
Surgery vs Non-Surgical Management for MBO |
3/9/2015 |
|
100% |
|
|
Closed |
S1500 |
PhII: MET inhibitors for papillary RCC |
4/5/2016 |
|
100% |
|
|
Closed |
S1417CD |
Impact of Cancer on Finances |
4/15/2016 |
2/1/2019 |
100% |
|
|
Closed |
S1416 |
Ph II Cisplatin +/- ABT 888 in Metastatic TNBC and/or BRCA |
7/7/2016 |
6/15/2019 |
100% |
|
|
Closed |
S1507 |
Ph II Tram + doce with kras NSCLC + and PD |
7/18/2016 |
3/15/2018 |
100% |
|
|
Closed |
S1512 |
Desmoplastic study |
10/20/2016 |
|
100% |
|
|
Closed |
S1602 |
BCG Strain Differences and BCG vaccination in High-Grade Non-Muscle Invasive Bladder Cancer |
2/7/2017 |
12/15/2020 |
100% |
|
|
Closed |
S1616 |
Ipilimumab + Nivolmab in Adv Melanoma follow prog on PD-1 Inhibitor |
7/17/2017 |
|
100% |
|
|
Closed |
S1619 |
Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab |
11/3/2017 |
5/1/2020 |
100% |
|
|
Closed |
S1702 |
Ph II AL amyloidosis isatuximab |
3/8/2018 |
9/30/2019 |
100% |
|
|
Open |
S1803 |
PIII Daratumumab + Lenalidomide Post-Auto SCT Maint for MM |
6/27/2019 |
|
100% |
|
|
Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
Closed |
S1801 |
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma |
12/6/2018 |
5/5/2022 |
100% |
|
|
Closed |
S1600 |
Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes |
2/21/2019 |
10/20/2023 |
100% |
|
|